Immunovia - Discover and develop tools for early diagnosis of cancers

March 29, 2021
Immunovia reports historical breakthrough in early detection of pancreatic cancer in high risk groups

IMMray™ PanCan-d blood test detects early stage pancreatic cancers with 98% specificity and 85% sensitivity in large blinded clinical validation study of familial hereditary risk group cohorts in USA

IMMray™ PanCan-d shows improved test performance and demonstrates specificity / sensitivity of 92% / 80% in detecting early stage pancreatic cancers in clinical study with high risk symptomatic patient cohorts

LATEST WEBINAR
45 min

Press releases

April 21, 2021

Immunovia presents update on US market size for IMMray™ PanCan-d in the familial/hereditary risk group

April 21, 2021

Invitation to Presentation of Immunovia’s Interim Report January – March 2021

April 16, 2021

IMMray™ PanCan-d highlighted in meeting arranged by Pancreatic Cancer Action Network

Financial reports

February 2021

Immunovia AB published the company’s Full Year Report 2020 on Wednesday, February 17, 2021, at 4.00 p.m. CET.

Immunovia Full Year Report 2020 (PDF in English)

Immunovia Full Year Report 2020 (PDF in Swedish)

Financial reports

Calendar

28 April, 2021

Interim Report Jan-March 2021

Place: Immunovia website

30 April-1 May, 2021

92nd EGPRN (European GP research network) meeting – Virtual event

Place: Halle, Germany, Virtual event

4-6 May, 2021

Swedish Gastro Days – Virtual event

Place: Borås, Sweden - Virtual event